Transsphenoidal surgery for prolactinomas in male patients: a retrospective study.
- Author:
Wei-Jie SU
1
;
Hong-Cai CAI
2
;
Guo-Chen YANG
1
;
Ke-Jun HE
1
;
Hong-Lin WU
1
;
Yi-Bing YANG
1
;
Hong-Xing TANG
1
;
Li-Xuan YANG
1
;
Chun-Hua DENG
2
Author Information
- Publication Type:Journal Article
- Keywords: erectile dysfunction; prolactinomas; sexual dysfunction; transsphenoidal surgery
- MeSH: Humans; Male; Prolactinoma/surgery*; Erectile Dysfunction/etiology*; Retrospective Studies; Sexual Dysfunction, Physiological/complications*; Testosterone; Pituitary Neoplasms/pathology*
- From: Asian Journal of Andrology 2023;25(1):113-118
- CountryChina
- Language:English
- Abstract: Male patients with prolactinomas usually present with typical hyperprolactinemia symptoms, including sexual dysfunction and infertility. However, clinical factors related to sexual dysfunction and surgical outcomes in these patients remain unclear. This study aimed to investigate the outcomes of male patients with prolactinomas after transsphenoidal surgery and the risk factors affecting sexual dysfunction. This study was conducted on 58 male patients who underwent transsphenoidal surgery for prolactinomas between May 2014 and December 2020 at the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. We evaluated the sexual function of patients before and after surgery through International Index of Erectile Function-5 scores, libido, and frequency of morning erection. Of the 58 patients, 48 (82.8%) patients had sexual intercourse preoperatively. Among those 48 patients, 41 (85.4%) patients presented with erectile dysfunction. The preoperative International Index of Erectile Function-5 scores in patients with macroprolactinomas were significantly higher than those in patients with giant prolactinomas (17.63 ± 0.91 vs 13.28 ± 1.43; P = 0.01). Postoperatively, the incidence of erectile dysfunction was 47.9%, which was significantly lower than that preoperatively (85.4%; P = 0.01). Twenty-eight (68.3%) patients demonstrated an improvement in erectile dysfunction. Tumor size and invasiveness were significantly correlated with the improvement of erectile dysfunction. Preoperative testosterone <2.3 ng ml-1 was an independent predictor of improvement in erectile dysfunction. In conclusion, our results indicated that tumor size and invasiveness were important factors affecting the improvement of sexual dysfunction in male patients with prolactinoma. The preoperative testosterone level was an independent predictor related to the improvement of erectile dysfunction.
